CLINICAL STAGE IVA GASTRIC CANCER AJCC V8
Clinical trials for CLINICAL STAGE IVA GASTRIC CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE IVA GASTRIC CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE IVA GASTRIC CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Radiation boosts chemo for stomach and esophageal cancer?
Disease control OngoingThis study tests whether adding radiation therapy to standard chemotherapy helps people with HER2-negative esophageal or stomach cancer that has spread to a few other spots in the body (oligometastatic). About 314 participants will receive either chemotherapy alone or chemotherap…
Matched conditions: CLINICAL STAGE IVA GASTRIC CANCER AJCC V8
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 26, 2026 04:36 UTC
-
New cocktail of immune drugs and radiation shows promise against stomach cancer
Disease control OngoingThis study tests whether giving two immunotherapy drugs (nivolumab and ipilimumab) along with chemotherapy and radiation before surgery can help treat stomach cancer that is still removable. About 32 adults with early-stage stomach or gastroesophageal junction cancer will receive…
Matched conditions: CLINICAL STAGE IVA GASTRIC CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:36 UTC
-
Shorter radiation before stomach cancer surgery shows promise in early trial
Disease control OngoingThis early-phase trial tests whether a shorter course (2 weeks instead of 5) of chemoradiotherapy followed by standard chemotherapy is safe and effective for people with stomach cancer who will have surgery. About 25 participants will receive the shorter radiation plus chemo befo…
Matched conditions: CLINICAL STAGE IVA GASTRIC CANCER AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New way to deliver chemotherapy shows promise for stomach cancer patients
Disease control OngoingThis early-phase trial is testing the safety and best dose of the chemotherapy drug paclitaxel when given directly into the abdomen (intraperitoneal) for people with advanced stomach or gastroesophageal cancer that has spread to the lining of the abdomen. The study includes 27 pa…
Matched conditions: CLINICAL STAGE IVA GASTRIC CANCER AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New hope for stomach cancer: immunotherapy combo shows promise in genetic subtype
Disease control OngoingThis study tests whether the immunotherapy drug atezolizumab, alone or with chemotherapy, can shrink or control a specific type of stomach or gastroesophageal junction cancer that has a high number of genetic mutations (MSI-H/dMMR). About 240 adults with early-stage but resectabl…
Matched conditions: CLINICAL STAGE IVA GASTRIC CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 19, 2026 11:47 UTC